Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKYANASDAQ:ISONASDAQ:NAUTNASDAQ:PRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKYAAkoya Biosciences$1.26-3.1%$1.24$0.93▼$3.42$62.84M1.34396,507 shs404,396 shsISOIsoPlexis$0.76$0.86$0.60▼$5.10$30.28M1.3268,375 shsN/ANAUTNautilus Biotechnology$0.73-6.6%$0.79$0.66▼$3.09$92.35M1.41117,876 shs195,236 shsPREPrenetics Global$10.31-8.2%$4.90$3.09▼$12.72$125.83M-0.2618,856 shs63,279 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKYAAkoya Biosciences0.00%+30.01%+11.11%-36.74%-43.11%ISOIsoPlexis0.00%0.00%0.00%0.00%0.00%NAUTNautilus Biotechnology-0.08%-9.46%+0.26%-49.09%-71.70%PREPrenetics Global+38.81%+93.96%+149.56%+107.39%+93.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKYAAkoya Biosciences1.2833 of 5 stars3.01.00.00.01.41.70.6ISOIsoPlexisN/AN/AN/AN/AN/AN/AN/AN/ANAUTNautilus Biotechnology2.3087 of 5 stars3.02.00.00.00.04.20.6PREPrenetics Global0.8825 of 5 stars1.55.00.00.00.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKYAAkoya Biosciences 2.00Hold$2.5198.89% UpsideISOIsoPlexis 0.00N/AN/AN/ANAUTNautilus Biotechnology 2.00Hold$2.42230.10% UpsidePREPrenetics Global 3.00Buy$9.00-12.71% DownsideCurrent Analyst Ratings BreakdownLatest ISO, NAUT, PRE, and AKYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025AKYAAkoya BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$1.80 ➝ $1.084/29/2025AKYAAkoya BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$3.50 ➝ $1.804/14/2025AKYAAkoya BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.40 ➝ $1.653/25/2025AKYAAkoya BiosciencesStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$3.50 ➝ $1.803/18/2025AKYAAkoya BiosciencesStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$3.50 ➝ $3.503/5/2025AKYAAkoya BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$2.402/28/2025NAUTNautilus BiotechnologyGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.50(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKYAAkoya Biosciences$79.96M0.79N/AN/A$1.10 per share1.15ISOIsoPlexis$16.76M1.81N/AN/A$1.04 per share0.73NAUTNautilus BiotechnologyN/AN/AN/AN/A$2.12 per shareN/APREPrenetics Global$30.62M4.11N/AN/A$17.22 per share0.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKYAAkoya Biosciences-$63.32M-$0.97N/AN/AN/A-66.77%-162.99%-32.76%8/4/2025 (Estimated)ISOIsoPlexis-$106M-$2.70N/AN/AN/A-632.41%-127.86%-71.41%N/ANAUTNautilus Biotechnology-$63.67M-$0.54N/AN/AN/AN/A-28.85%-24.93%7/29/2025 (Estimated)PREPrenetics Global-$62.72M-$3.99N/AN/AN/A-191.73%-16.45%-13.34%6/17/2025 (Estimated)Latest ISO, NAUT, PRE, and AKYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AKYAAkoya Biosciences-$0.29-$0.32-$0.03-$0.32$20.19 million$16.64 million4/29/2025Q1 2025NAUTNautilus Biotechnology-$0.14-$0.13+$0.01-$0.13N/AN/A3/17/2025Q4 2024AKYAAkoya Biosciences-$0.15-$0.17-$0.02-$0.17$21.34 million$21.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKYAAkoya BiosciencesN/AN/AN/AN/AN/AISOIsoPlexisN/AN/AN/AN/AN/ANAUTNautilus BiotechnologyN/AN/AN/AN/AN/APREPrenetics Global$2.8027.16%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKYAAkoya Biosciences5.622.751.85ISOIsoPlexis1.124.062.50NAUTNautilus BiotechnologyN/A16.6516.65PREPrenetics GlobalN/A1.401.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKYAAkoya Biosciences79.42%ISOIsoPlexis44.91%NAUTNautilus Biotechnology50.71%PREPrenetics Global25.01%Insider OwnershipCompanyInsider OwnershipAKYAAkoya Biosciences7.30%ISOIsoPlexis6.40%NAUTNautilus Biotechnology41.10%PREPrenetics Global7.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKYAAkoya Biosciences9049.88 million45.95 millionOptionableISOIsoPlexis45939.76 million37.22 millionNot OptionableNAUTNautilus Biotechnology130126.15 million74.71 millionOptionablePREPrenetics Global112.21 million11.25 millionNot OptionableISO, NAUT, PRE, and AKYA HeadlinesRecent News About These CompaniesPrenetics Global (NASDAQ:PRE) Shares Down 2.6% - Should You Sell?May 15, 2025 | marketbeat.comPrenetics Global Full Year 2024 Earnings: Misses ExpectationsMay 3, 2025 | finance.yahoo.comPrenetics Global Limited (PRENW)March 19, 2025 | ca.finance.yahoo.comPrenetics’ IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements MarketMarch 18, 2025 | markets.businessinsider.comPrenetics' IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements MarketMarch 18, 2025 | globenewswire.comPrenetics to Participate in the 37th Annual ROTH ConferenceMarch 11, 2025 | finance.yahoo.comPrenetics Reports Strong 2024 Results and Optimistic 2025 OutlookMarch 5, 2025 | tipranks.comPrenetics Global Limited Reports 93.5% Revenue Growth in Q4 2024 and Provides 2025 Financial GuidanceMarch 5, 2025 | quiverquant.comPrenetics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 GuidanceMarch 5, 2025 | globenewswire.comNYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR FEBRUARY 14th + KARMAN POPS DOUBLE DIGIT IPOFebruary 14, 2025 | prnewswire.comPrenetics Global Ltd trading resumesFebruary 12, 2025 | markets.businessinsider.comPrenetics Global Ltd trading halted, volatility trading pauseFebruary 12, 2025 | markets.businessinsider.comPrenetics partners with Humanity Protocol, launches crypto strategic reserveFebruary 11, 2025 | markets.businessinsider.comPrenetics Partners with Humanity Protocol to Enhance Blockchain-Based Identity Verification and Invests in Digital AssetsFebruary 11, 2025 | quiverquant.comNasdaq-Listed Prenetics Announces Genomics-Based Partnership with Humanity Protocol and Launches Crypto Strategic ReserveFebruary 11, 2025 | globenewswire.comPrenetics Unveils IM8 to U.S. Consumers with Co-Founding Partner David BeckhamJanuary 22, 2025 | markets.businessinsider.comCantor Fitzgerald Sticks to Their Buy Rating for Prenetics Group (PRE)January 16, 2025 | markets.businessinsider.comIM8, Co-Founded by David Beckham, Achieves NSF Certified for Sport® Certification for Daily Ultimate Essentials SupplementJanuary 15, 2025 | quiverquant.comPrenetics' IM8 Achieves Prestigious NSF Certified for Sport® for Daily Ultimate EssentialsJanuary 15, 2025 | globenewswire.comDavid Beckham Joins Prenetics as Strategic Investor for IM8 Health BrandJanuary 14, 2025 | lawyer-monthly.comHow David Beckham plans to win the $152 billion supplements businessJanuary 14, 2025 | fastcompany.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumHow Does D-Wave Stack Up Against Quantum Competitors?By Nathan Reiff | May 20, 2025View How Does D-Wave Stack Up Against Quantum Competitors?Broadcom's VMware Deal Lifts AVGO Despite Complaints By Leo Miller | April 28, 2025View Broadcom's VMware Deal Lifts AVGO Despite Complaints After Earnings Beats, These 3 Stocks Are on Analysts’ RadarsBy Leo Miller | May 20, 2025View After Earnings Beats, These 3 Stocks Are on Analysts’ RadarsUPS Stock Forecast: Rebound Underway for United Parcel Service?By Thomas Hughes | May 4, 2025View UPS Stock Forecast: Rebound Underway for United Parcel Service?ISO, NAUT, PRE, and AKYA Company DescriptionsAkoya Biosciences NASDAQ:AKYA$1.26 -0.04 (-3.08%) Closing price 04:00 PM EasternExtended Trading$1.26 0.00 (-0.32%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.IsoPlexis NASDAQ:ISOIsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.Nautilus Biotechnology NASDAQ:NAUT$0.73 -0.05 (-6.62%) Closing price 04:00 PM EasternExtended Trading$0.74 +0.01 (+1.08%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Prenetics Global NASDAQ:PRE$10.31 -0.92 (-8.19%) Closing price 03:59 PM EasternExtended Trading$11.00 +0.68 (+6.64%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
